MNTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Momenta Pharmaceuticals's share price is $52.48. Momenta Pharmaceuticals's Tangible Book per Share of Jun. 2020 for the quarter that ended in Jun. 2020 was $3.32. Hence, Momenta Pharmaceuticals's Price to Tangible Book Ratio of today is 15.79.
The historical rank and industry rank for Momenta Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Momenta Pharmaceuticals's highest Price to Tangible Book Ratio was 15.81. The lowest was 1.52. And the median was 3.26.
A closely related ratio is called PB Ratio. As of today, Momenta Pharmaceuticals's share price is $52.48. Momenta Pharmaceuticals's Book Value per Sharefor the quarter that ended in Jun. 2020 was $3.33. Hence, Momenta Pharmaceuticals's P/B Ratio of today is 15.75.
The historical data trend for Momenta Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momenta Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 2.80 | 2.92 | 2.88 | 2.37 | 5.08 |
Momenta Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 3.96 | 4.68 | 5.08 | 7.50 | 10.01 |
For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Momenta Pharmaceuticals's Price-to-Tangible-Book falls into.
Momenta Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Jun. 2020 ) |
= | 52.48 | / | 3.324 | |
= | 15.79 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce Downey | director | |
Alejandra Carvajal | officer: Chief Legal Officer | C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
Jose-carlos Gutierrez-ramos | director | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Elizabeth Stoner | director | C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142 |
Santiago Arroyo | officer: SVP, Chief Medical Officer | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Young Kwon | officer: Chief Financial & Bus. Officer | C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Ian Fier | officer: Chief Mfg and Program Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Jo Ann Beltramello | officer: Chief HR and Inf. Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Anthony M. Manning | officer: Chief Scientific Officer | C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Donna Roy Grogan | director | 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633 |
Agnieszka Cieplinska | officer: Chief Accounting Officer (PAO) | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Craig A Wheeler | director, officer: President & CEO |
From GuruFocus
By PRNewswire PRNewswire • 09-26-2020
By [email protected] insider • 02-12-2020
By [email protected] insider • 03-09-2020
By Marketwired Marketwired • 08-19-2020
By Marketwired Marketwired • 06-15-2020
By Marketwired Marketwired • 08-19-2020
By [email protected] insider • 06-18-2020
By Business Wire Business Wire • 08-19-2020
By PRNewswire PRNewswire • 08-22-2020
By PRNewswire PRNewswire • 08-20-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.